Want to see NOVT full AI Analyst Report?
NOVT Stock Chart & Stats
$143.96
-$0.74(-0.52%)
At close: 4:00 PM EDT
$143.96
-$0.74(-0.52%)
Day’s Range― - ―
52-Week Range$98.27 - $176.38
Previous Close$140.8
Volume290.87K
Average Volume (3M)412.98K
Market Cap
$5.13B
Enterprise Value$6.22B
Total Cash (Recent Filing)$718.65M
Total Debt (Recent Filing)$282.82M
Price to Earnings (P/E)88.0
Beta1.79
Next Earnings
Nov 09, 2026EPS Estimate
0.97Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.59
Shares Outstanding37,817,770
10 Day Avg. Volume503,613
30 Day Avg. Volume412,977
Financial Highlights & Ratios
PEG Ratio-4.65
Price to Book (P/B)3.31
Price to Sales (P/S)4.44
P/FCF Ratio89.90
Enterprise Value/Market Cap1.21
Enterprise Value/Revenue6.04
Enterprise Value/Gross Profit14.21
Enterprise Value/Ebitda40.33
Forecast
1Y Price Target
$194.00Price Target Upside34.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)3.69
Revenue Forecast (FY)$1.13B
Bulls Say, Bears Say
Bulls Say
New-product And Backlog MomentumRapid new-product adoption, stronger bookings and backlog growth support durable demand for Novanta’s engineered components. Design wins can embed products in OEM platforms, improving recurring production-life revenue and reinforcing the company’s technology position.
Strong Cash GenerationStrong operating and free cash flow provide internal funding for product development, integration and debt reduction. Free cash flow at roughly 85% of net income also indicates meaningful earnings quality, although annual conversion has shown some volatility.
Strategic Medical ExpansionThe Riverpoint acquisition expands Novanta’s recurring medical consumables platform and broadens its addressable market through shared OEM relationships. Management expects immediate growth, margin, EBITDA and cash-flow accretion, strengthening the medical technology mix.
Bears Say
Compressed Operating MarginsMargin compression reduces the amount of revenue that converts into operating earnings and can constrain reinvestment capacity. Medical mix, transformation costs and site rationalization are weighing on profitability, making sustained margin recovery important to the investment case.
Higher Acquisition LeverageRiverpoint financing materially increases gross debt and makes deleveraging a more important capital-allocation priority. Higher leverage can limit flexibility for additional acquisitions or investment and increases the importance of reliable cash generation during integration.
Weak Precision Medicine And Life SciencesWeakness in precision medicine and life sciences creates a persistent drag on portfolio growth and mix. Commoditization can also limit pricing and profitability, while management’s recovery target in late 2027 implies these businesses may remain a multi-quarter headwind.
NOVT FAQ
What was Novanta Inc’s price range in the past 12 months?
Novanta Inc lowest stock price was $98.27 and its highest was $176.38 in the past 12 months.
What is Novanta Inc’s market cap?
Novanta Inc’s market cap is $5.13B.
When is Novanta Inc’s upcoming earnings report date?
Novanta Inc’s upcoming earnings report date is Nov 09, 2026 which is in 18 days.
How were Novanta Inc’s earnings last quarter?
Novanta Inc released its earnings results on Aug 05, 2026. The company reported $0.89 earnings per share for the quarter, beating the consensus estimate of $0.83 by $0.06.
Is Novanta Inc overvalued?
According to Wall Street analysts Novanta Inc’s price is currently Undervalued.
Does Novanta Inc pay dividends?
Novanta Inc does not currently pay dividends.
What is Novanta Inc’s EPS estimate?
Novanta Inc’s EPS estimate is 0.97.
How many shares outstanding does Novanta Inc have?
Novanta Inc has 37,817,770 shares outstanding.
What happened to Novanta Inc’s price movement after its last earnings report?
Novanta Inc reported an EPS of $0.89 in its last earnings report, beating expectations of $0.83. Following the earnings report the stock price went up 6.661%.
Which hedge fund is a major shareholder of Novanta Inc?
Currently, no hedge funds are holding shares in NOVT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novanta Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$194.00 (34.76% Upside)
$194.00 (34.76% Upside)
Blogger Sentiment
Neutral
NOVT Sentiment 67%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Decreased
By 250.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 8.1%
Last 30 Days ▲ 8.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
23.84%
12-Months-Change
Fundamentals
Return on Equity
4.90%
Trailing 12-Months
Asset Growth
41.59%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Novanta Inc
Operating globally, Novanta Inc. and its affiliated companies specialize in the development, production, and distribution of advanced photonics, vision, and precision motion components and sub-assemblies. These highly engineered solutions are supplied to Original Equipment Manufacturers (OEMs) across the medical and industrial sectors. Within its Photonics division, Novanta provides a suite of laser-driven technologies. These encompass systems for laser scanning, beam manipulation, and various laser types such as CO2, solid-state, ultrafast, and optical light engines. Their applications span critical areas like industrial manufacturing, precision measurement (metrology), advanced imaging in healthcare and biological research, DNA sequencing, and specialized medical laser treatments. The Vision segment delivers an array of medical-grade innovations. This portfolio comprises instruments like medical insufflators, pumps, and their associated consumables, alongside comprehensive visualization tools. It also features wireless communication systems, video recording devices, and integration platforms designed for operating theaters. Further offerings include optical data acquisition, machine vision systems, radio frequency identification (RFID) solutions, thermal recording devices, spectrometry equipment, and integrated touchscreen displays. Furthermore, the Precision Motion division specializes in supplying components such as optical and inductive encoders, high-precision motors, servo drives, and complete motion control systems. This segment also delivers integrated stepper motors, sophisticated robotic end-effectors, air bearings, and air bearing spindles. Novanta distributes its extensive product lines through various channels, including its dedicated direct sales team, value-added resellers, distribution partners, and system integrators. These offerings are available under well-known brand names such as Cambridge Technology, Synrad, Laser Quantum, ARGES, WOM, NDS, NDSsi, Med X Change, Reach Technology, JADAK, ThingMagic, Photo Research, Celera Motion, MicroE, Zettlex, Applimotion, Ingenia, and Westwind. Founded in 1968, the company operated as GSI Group, Inc. until its rebranding to Novanta Inc. in May 2016. Its corporate headquarters are located in Bedford, Massachusetts.
NOVT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call was positive: management reported broad-based organic growth, margin expansion, strong cash generation, significant new product momentum, and closed an accretive strategic acquisition (Riverpoint) that raises guidance. There are manageable near-term headwinds — lower medical segment margins from mix and transformation costs, supply-chain/tariff pressures, integration and restructuring expenses, and a temporary rise in gross leverage from acquisition financing — but management provided clear plans and guidance to offset these over time. The highlights materially outweigh the lowlights.View all NOVT earnings summariesNOVT Stock 12 Month Forecast
Average Price Target
$194.00
▲(34.76% Upside)
Technical Analysis
Ownership Overview
0.71% Insiders
43.47% Mutual Funds
6.95% Other Institutional Investors
18.41% Public Companies and
Individual Investors










